Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Infection by hepatitis C virus (HCV) affects more than 170 million people in the World and 80.000 in Chile. It causes more deaths than HIV infection in the US and is a leading cause for liver transplantation in Chile. Even though treatments are evolving with new direct antiviral agents (DAAs) that are increasing response rates, there are several issues with these new approaches, including increased toxicity, need for using interferon and ribavirin, complex algorithms of treatment, high cost, limited effectivity in certain groups (liver transplant patients) and drug interactions. Treatments targeted at host factors required for the viral cycle are becoming increasingly explored as an alternative or complement to DAAs. It has been recently described that Niemann-Pick C1-like 1 (NPC1L1), the intestinal receptor of cholesterol, serves as an entry factor for HCV. NPC1L1 is, therefore, a key transporter in the enterohepatic cycle of cholesterol. NPC1L1 can be blocked with ezetimibe, which is an approved and generally safe drug used for the management of hypercholesterolemia. Our hypothesis posits that blocking HCV entry to the hepatocyte or intestinal HCV reabsorption with ezetimibe may have an antiviral effect. In the study, we will administer ezetimibe 20 mg/d to 20 patients with stable chronic hepatitis C for 12 weeks and assess changes in HCV RNA and core antigen in plasma, bile and feces.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C

NCT02971033

Chronic Hepatitis C

TERMINATED PHASE2

Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C

NCT02118012

Chronic Hepatitis C

COMPLETED PHASE1/PHASE2

A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients

NCT01567540

Hepatitis C

TERMINATED PHASE1

Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.

NCT01195181

Hepatitis C Virus Chronic Liver Disease Viral Hepatitis +2 more

COMPLETED PHASE4

Hepatitis C Rimantadine and Antiviral Combination Therapy

NCT01413490

Hepatitis C

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ezetimibe

Ezetimibe administered by mouth 10 mg BID for 12 weeks

Group Type EXPERIMENTAL

Ezetimibe

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ezetimibe

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic hepatitis C defined as detectable HCV RNA for more than 6 months.
* Age \> 18 years old.
* Compensated liver disease (bilirubin \< 3mg/dL, unless having Gilbert´s syndrome, albumin \> 3 g/dL, INR \< 2, no hepatic encephalopathy, no ascites or recent -1 month- history of variceal bleeding).
* HCV RNA level \> 10.000 IU/mL.
* Signed informed consent document.

Exclusion Criteria

* History of cholecystectomy or known gallstones.
* Current HCV antiviral treatment.
* Medications for dyslipidemia in the preceding 2 months.
* Abdominal surgery that could alter biliary or intestinal anatomy.
* Evidence of sitosterolemia.
* Negative pregnancy test in urine (for females).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No